High-purity exosome standards improve EV research reproducibility

Amsbio introduces a comprehensive range of lyophilised exosome standards designed to enhance reproducibility and standardisation in extracellular vesicle (EV) studies.

Exosomes - tiny lipid nanoparticles secreted by most living cells - play crucial roles in various physiological and pathological processes. Their involvement in cancer, infectious diseases, and neurodegenerative disorders has sparked growing interest in their potential as biomarkers and therapeutic agents.

As the importance of reproducible extracellular vesicle (EV) research gains global recognition, the International Society for Extracellular Vesicles (ISEV) highlighted this focus in its 2023 guidelines. Amsbio’s exosome standards directly support these priorities by providing high-purity, quality-controlled reference materials that enable consistent comparison across laboratories and studies. To learn more about how exosomes are advancing diagnostics and therapeutics - and the crucial role of standards in this progress - read Amsbio’s detailed blog.

Sourced from diverse biological materials - including cell culture supernatant, human plasma, serum, and urine - Amsbio exosomes undergo rigorous purification via tangential flow filtration (TFF) and size exclusion chromatography (SEC). Each batch is thoroughly characterised for protein content, size distribution, particle concentration, and expression of EV-specific markers.

Freeze-dried to maintain structural integrity, these standards remain stable at 4°C for up to 36 months. Their stringent quality control supports reliable experimental outcomes and cross-study comparability.

Quick to reconstitute, Amsbio exosome standards serve as trusted positive controls in applications such as marker validation, EV quantification, flow cytometry, immunocapture testing, and OMICS analyses. Fluorescent labelling options are also available.

More information online